Omnicell (OMCL) has announced new products aimed at streamlining workflows and improving inventory visibility and management in perioperative and clinic settings. The offerings are a new line of RFID products, MedTrack, and a web-enabled software product named MedVision.The latest development expands the company’s connected platform, intended to automate medication management processes and deliver intelligent insights to drive clinical and operational outcomes across all settings of care.OMCL Stock’s Likely ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 OMNI ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .Today, we are going to put Omnicell, Inc. ( OMCL ) , a small-cap medical technology solutions provider in the spotlight for the first time. The company just posted its Q1 results o ...

Omnicell, Inc. (OMCL) reported first-quarter 2025 adjusted earnings per share (EPS) of 26 cents compared with 3 cents in the year-ago period. The metric beat the Zacks Consensus Estimate by 62.5%. Adjustments include one-time expenses like share-based compensations, the amortization of acquired intangibles, acquisition-related expenses and RDS restructuring. GAAP loss per share was 15 cents compared with a loss of 34 cents in the year-ago period. Following the announcement, OMCL shares gained 3.7% in the af ...

Omnicell, Inc. (NASDAQ:OMCL) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Kathleen Nemeth - SVP, IR Randall Lipps - Founder, Chairman, President and CEO Nchacha Etta - EVP and CFO Nnamdi Njoku - COO Conference Call Participants Jessica Datson - Piper Sandler Gene Mannheimer - Freedom Capital Markets Allen Lutz - Bank of America Bill Sutherland - Benchmark Stan Berenshteyn - Wells Fargo Matt Hewitt - Craig-Hallum Capital David Larsen - BTIG Operator Good morning, my name is Ca ...

Omnicell (OMCL) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Company Participants Kathleen Nemeth - Senior Vice President, Investor RelationsRandall Lipps - Founder, Executive Chairman, President & CEONchacha Etta - Executive VP & CFONnamdi Njoku - EVP & COOBill Sutherland - Director of ResearchDavid Larsen - Managing Director Conference Call Participants Jessica Tassan - Senior Equity Research AnalystGene Mannheimer - Managing Director, Senior Research AnalystAllen Lutz - Senior Equity Research AnalystSt ...

Omnicell (OMCL) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Speaker0 Good morning. My name is Carly, and I will be your conference operator today. At this time, I would like to welcome everyone to the Omnicell First Quarter twenty twenty five Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. Thank you. I would now like to turn the call over to Kathleen Nemeth, Senior Vice Preside ...

Investor Presentation May 6, 2025 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of federal securities laws. These forward-looking statements include statements with respect to 2025 guidance, strategic and growth opportunities, other expectations and other non-historical information. Without limiting the foregoing, statements including the words "expect," "intend," "may," "will," "should," "would," "could," "plan," "potential," "anticipate," "believe," ...

Financial Performance - Total revenues for Q1 2025 were $270 million, an increase of $24 million or 10% compared to Q1 2024, driven by growth in the XT Amplify program and SaaS services [3]. - Non-GAAP net income for Q1 2025 was $12 million, or $0.26 per diluted share, compared to $1 million, or $0.03 per diluted share in Q1 2024 [4]. - Non-GAAP EBITDA for Q1 2025 was $24 million, up from $11 million in Q1 2024 [5]. - Total revenues for Q1 2025 reached $269.7 million, a 9.5% increase from $246.2 million in Q1 2024 [29]. - Gross profit for Q1 2025 was $110.9 million, compared to $92.6 million in Q1 2024, reflecting a gross margin improvement [29]. - Net loss for Q1 2025 was $7.0 million, a reduction from a net loss of $15.7 million in Q1 2024, indicating improved operational efficiency [29]. - Non-GAAP net income for Q1 2025 was $12,354,000, significantly higher than $1,220,000 in Q1 2024 [39]. - Non-GAAP EBITDA for Q1 2025 reached $23,593,000, compared to $10,837,000 in Q1 2024, reflecting a non-GAAP EBITDA margin of 8.7% versus 4.4% [39]. - The company generated $25,924,000 in net cash from operating activities in Q1 2025, down from $49,953,000 in Q1 2024 [41]. - Non-GAAP free cash flow for Q1 2025 was $10,185,000, a decrease from $37,613,000 in Q1 2024 [41]. - The company reported a net loss of $7,023,000 for Q1 2025, an improvement from a net loss of $15,676,000 in Q1 2024 [35]. Balance Sheet and Cash Flow - As of March 31, 2025, cash and cash equivalents totaled $387 million, with total debt of $341 million and total assets of $2.2 billion [6]. - Cash and cash equivalents increased to $386.8 million as of March 31, 2025, up from $369.2 million at the end of 2024 [31]. - Total assets grew to $2.15 billion as of March 31, 2025, compared to $2.12 billion at the end of 2024, indicating solid asset management [31]. - Total stockholders' equity increased to $1.26 billion as of March 31, 2025, from $1.24 billion at the end of 2024, reflecting positive shareholder value [33]. - Omnicell has $350 million available under its revolving credit facility with no outstanding balance as of March 31, 2025 [7]. - The company’s total cash, cash equivalents, and restricted cash at the end of Q1 2025 was $414,402,000, down from $549,962,000 at the end of Q1 2024 [35]. Operational Efficiency and Cost Management - The company is focusing on mitigating potential tariff impacts on its supply chain while maintaining strong free cash flow [2]. - Omnicell plans to maintain its focus on operational efficiency and cost management while pursuing growth opportunities in the market [24]. - Research and development expenses decreased to $20.5 million in Q1 2025 from $22.1 million in Q1 2024, showing a focus on cost management [29]. - The company’s GAAP operating expenses were $122,555,000 in Q1 2025, representing 45.4% of total revenues, compared to 46.5% in Q1 2024 [37]. - Share-based compensation expense increased to $10,786,000 in Q1 2025 from $8,641,000 in Q1 2024 [39]. Future Guidance and Investments - The company updated its full-year 2025 guidance, projecting total revenues between $1.105 billion and $1.155 billion [10]. - Annual recurring revenue is expected to be between $610 million and $630 million for 2025 [10]. - The company continues to invest in research and development to enhance product offerings and market competitiveness [23]. - The company plans to open the Austin Innovation Lab on May 14, 2025, to enhance product development and innovation [15].

Core Insights - Zacks Premium provides various tools to enhance investor confidence and market engagement, including daily updates on Zacks Rank and Industry Rank, Equity Research reports, and Premium stock screens [1][2] Zacks Style Scores - Zacks Style Scores rate stocks based on value, growth, and momentum, serving as complementary indicators to the Zacks Rank, helping investors identify securities likely to outperform the market in the next 30 days [3][4] - Stocks are rated from A to F, with A indicating the highest potential for outperformance [4] Value Score - The Value Score identifies attractive and discounted stocks using ratios like P/E, PEG, Price/Sales, and Price/Cash Flow, appealing to value investors [4] Growth Score - The Growth Score focuses on a company's financial strength and future outlook, analyzing projected and historical earnings, sales, and cash flow to find stocks with sustainable growth [5] Momentum Score - The Momentum Score capitalizes on price trends, using factors like one-week price change and monthly earnings estimate changes to identify favorable times for investment [6] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator that evaluates stocks based on value, growth, and momentum [7] Zacks Rank - The Zacks Rank is a proprietary model based on earnings estimate revisions, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [8][9] - There are over 800 top-rated stocks available, making it essential for investors to utilize Style Scores to narrow down choices [10] Stock Highlight: Omnicell Inc. (OMCL) - Omnicell Inc. specializes in end-to-end automation solutions for the medication-use process, including dispensing systems and decision support applications [13] - Currently rated 3 (Hold) with a VGM Score of A and a Value Style Score of B, OMCL has a forward P/E ratio of 17.19, indicating attractive valuation [14] - Recent upward revisions in earnings estimates for fiscal 2025 have increased the Zacks Consensus Estimate to $1.78 per share, with an average earnings surprise of 99.5% [14][15]